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IMPROVEMENT OF ASTHMA CONTROL AND INFLAMMATION IN PEDIATRIC PATIENTS
UNDERGOING ADENOTONSILLECTOMY. Jonathan C Levin, Lisa Gagnon, David E Karas, and Geoffrey
L Chupp. Section of Pulmonary and Critical Care, Department of Internal Medicine, Yale University
School of Medicine, New Haven, CT.
Observational studies have suggested improvement in asthma control after adenotonsillectomy, but
longitudinal studies that correlate the effect of the procedure on markers of airway inflammation
with changes in asthma control are limited. We conducted a longitudinal, observational study on 130
pediatric patients undergoing adenotonsillectomy, including 66 with asthma and 64 control subjects.
Asthma Control Test (ACT) scores, chitotriosidase (CHIT1) activity, and YKL-40 (CHI3L1) levels in the
circulation were measured at the time of surgery and at a 6-month follow-up visit, and genotypes of
chitinase family proteins were measured at baseline. Gene expression data was analyzed from blood,
tonsil, and nasal epithelial tissue samples at baseline and in the blood at follow-up by microarray
analysis. Mean ACT scores improved by 3 points (p< 0.001) after 6 months. 85% of children with
poorly-controlled asthma demonstrated an increase in ACT score of at least 3 points or a decrease in
Emergency Department/Urgent Care visits, oral corticosteroid courses, or rescue short acting
bronchodilator usage. Serum chitinase activity decreased significantly in children with asthma (p<
0.01), but not in children without asthma (p= 0.83) undergoing tonsillectomy. Higher chitinase
activity levels at baseline were associated with improved asthma control following surgery in all
children with asthma (p< 0.01) and in the subgroup of children with poorly-controlled asthma (p<
0.05). Subjects with asthma had a higher allele frequency of the CHIT1 mutation (p< 0.02). Gene
expression analysis identified a number of inflammatory genes differentially expressed in children
who had improved asthma control that were not changed in children without improved control and
control subjects. Of particular interest was SerpinB2, a plasmin activation inhibitor previously
implicated in asthma, significantly downregulated after surgery compared to baseline in children
with improved control. This data suggests that adenotonsillectomy improves asthma control by
modulation of airway inflammation. Elevated serum chitinase activity may be a clinically useful
determinant to identify patients with poorly-controlled asthma that will benefit from the procedure.
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Introduction
Asthma is an inflammatory disease of the lower airways that remains a significant
healthcare concern for the pediatric population despite public health and pharmacologic
advances to control the disease. (1, 2) Studies have demonstrated a systemic component to
asthmatic disease, and that the upper airway inflammation may be specifically involved in
the pathogenesis of asthma. (3-5) Upper airway infections and inflammation are common
in the pediatric population; likewise, respiratory infection and allergen exposure are
frequently indicated as triggers for asthma exacerbations in this population.
Adenotonsillectomy is one of the most common surgical procedures in children,
performed to address upper airway lymphoid hypertrophy, infection, and inflammation. (6)
Its clinical effect on asthma control has been debated, with observational studies
demonstrating a significant improvement in symptoms, lower healthcare utilization, and
reduction in controller or rescue medication usage following adenotonsillectomy. (7-10)
Although there are clear effects of adenotonsillectomy on the upper airway, to our
knowledge the effect of this procedure has not yet been studied on any markers of airway
inflammation.
Pediatric Asthma – Clinical Features and Pathophysiology
Asthma is the most common chronic disease of childhood; data from the 2009
National Health Statistics Reports showed that 9.6% of children 0-17 years of age (a total of
7.1 million) had asthma. 4.0 million children had at least one attack in 2009 and were at
risk for adverse outcomes such as Emergency Department visits or hospitalizations.
Asthma prevalence increased from 2001 to 2009. (1) Pediatric asthma has a significant
burden; in 2003, there were 12.8 million reported days of missed school due to childhood
asthma. In 2004, there were 198,000 total hospitalizations (3% of all pediatric admissions)
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and 750,000 visits to the emergency room (2.8% of pediatric visits) attributed to childhood
asthma; mortality rate was 2.5 per 1 million. (2)
Asthma is characterized by intermittent attacks that include symptoms of cough,
wheezing, and difficulty breathing. Attacks can be triggered by respiratory infections,
allergen exposure (e.g. dust mites, cockroach allergens, animal dander, and molds),
exposure to irritants (e.g. tobacco smoke), changes in weather, or exercise. Inflammation
results in hyperresponsive airways and causes bronchoconstriction and obstruction of
airflow. By definition, these symptoms are at least partially reversible. Obstructive changes
in airway physiology cause reductions in Forced Expiratory Volume (FEV1) > Forced Vital
Capacity (FVC) and a low FEV1/FVC ratio. In children, low FEV1 and FVC, along with a low
Forced Expiratory Flow (FEF) 25%-75%, are better predictors of disease than FEV1/FVC
ratio. (11)
Asthmatic inflammation is mediated by a variety of cell types including Th2
lymphocytes, eosinohpils, and mast cells. Th2 cytokines including IL-4, IL-5, and IL-13
produce inflammation that causes the pathophysiologic changes seen in asthma including
narrowing of the airways, mucus hypersecretion, and airway hyperresponsiveness. IgE
plays a pivotal role in this process as well. Airway remodeling occurs due to chronic
inflammation and leads to bronchial smooth muscle hypertrophy, mucous gland
hyperplasia, thickening of the subepithelial basemsent membrane due to collagen
deposition, and fibrotic changes. (12)
A Disease Beyond the Lower Airway
There is evidence that asthmatic disease exists beyond the lower airways. (3)
Upper airway respiratory infection and allergen exposure are frequently invoked as triggers
for exacerbations. Rhinovirus infection in the nasal airway has been shown to significantly
increase airway reactivity to both histamine and ragweed antigen, and predisposed patients
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to late asthmatic reactions to the challenge. (4) Another study showed that over 70% of
patients with asthma also have rhinitis, and this link has led to the “one airway hypothesis”,
defining asthma and rhinitis as two manifestations of one inflammatory process. (13) In
patients with rhinitis, provocation with a nasal allergen produces eosinophilic inflammation
in both the upper and lower airways, and provocation of the lower airway with an allergen
likewise produces in eosinophilic inflammation in both the upper and lower airways. (5)
Airway and nasal epithelial cells in both disease entities undergo similar structural and
inflammatory changes; likewise, corticosteroid therapy targeted at these epithelial cells is
effective for treatment of asthma as well as rhinitis. (14)
There are systemic components to this Th2 inflammation as well, reflected by
markers in the circulation. Inflammatory activity in the airways triggers eosinophil and
basophil recruitment from the bone marrow, producing a significantly higher number of
these cell types in the peripheral blood. (15) IL-4 and IL-13 induce B-lymphocytes to
produce IgE, which is elevated in the serum of asthmatics. (16) Blocking the effect of IgE
systemically with omalizumab (anti-IgE) has been shown to be an effective adjunctive
therapy for asthma in uncontrolled atopic patients with elevated IgE levels and allergen
hypperactivity proven by testing. (17) A number of other inflammatory markers in the
serum have also been shown to be associated with asthma, including IL-5 (18), eosinophil
cationic protein (19), IL-8, and TNF-α. (20) Asthma has also been associated with diseases
of other organ systems including atopic dermatitis, gastroesophageal reflux disease,
inflammatory bowel disease, obesity, obstructive sleep apnea, and cardiovascular disease.
(3)
Current Modalities of Treatment
The current cornerstone of recommendations for the management of asthma is the
control of symptoms and prevention of adverse outcomes. The Healthy People 2010
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initiative focuses on increasing the proportion of asthmatics receiving formal education and
appropriate care according to National Asthma Education and Prevention Program (NAEPP)
guidelines. However, it fell short of its stated goals, particularly in patients receiving an
asthma management plan with specific instructions on how to change the amount or type of
medicine taken, when to call a doctor for advice, and when to go to the ED. Report of
receiving this asthma education differed among groups, with generally higher rates among
children than adults and among non-Hispanic black patients than non-Hispanic white and
Mexican patients. (1)
Medical management is divided into two categories – controller medications to
reduce inflammation and “rescue” medications to reverse bronchospasm.

NAEPP

guidelines recommend a stepwise treatment to asthma. Children with intermittent asthma
are treated with rescue medications as needed. Albuterol, a short acting bronchodilator
(SABA) that relaxes airway smooth muscle and reverses bronchoconstriction, is the
cornerstone of such treatment.
Children with persistent asthma, as well as children whose asthma is not wellcontrolled, require “step ups” of treatment to daily controller medication.

Not well-

controlled asthma is defined by frequent symptoms and/or frequent use of SABAs (>2
days/week), nighttime awakenings, interference with normal activity, and 2 or more
exacerbations in a year requiring oral corticosteroid therapy. (21). The Asthma Control
Test (ACT) is a paper and web-based validated tool developed to assess level of disease
control over the last 4 weeks; the adult version assesses limitation at work or school,
shortness of breath, frequency of symptoms, frequency of rescue inhaler or medication use,
and self rating of control. (22) A pediatric version, validated for ages 4 to 11, includes four
questions directed at the child with a face and corresponding text (rate asthma today,
problem with exercise, cough, wake up at night), and 3 questions directed at the parent
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(frequency of daytime symptoms, frequency of wheeze, and frequency of nighttime
awakening). In both tests, a score of 19 or less suggests poor asthma control. (23) Data
supports that the minimally important difference for the ACT is 3 points. (24)
Daily controller medications include therapies targeting asthmatic inflammation,
such as inhaled corticosteroids (ICS), leukotriene modifiers, and the anti-IgE antibody
omalizumab. Long acting bronchodilators (LABAs) are also used in conjunction with ICS
therapy for patients with persistent asthma that do not achieve good control with inhaled
ICSs alone.
Adenotonsillectomy in Children and its Effect on Asthma
Adenotonsillectomy is one of the most common surgical procedures performed in
children. The superior part of the pharynx contains a ring of lymphoid tissue consisting of
the pharyngeal tonsils on the posterior wall of the nasopharynx (commonly known as the
adenoids) and two palatine tonsils (commonly known as “tonsils”) on either side of the
oropharynx. The tonsils and adenoids are most active between the ages of 4 and 10, and
then usually involute starting at puberty. As lymphoid tissue exposed to the environment,
the tonsils and adenoids can directly transport environmental antigens encountered on
their surfaces to the lymphoid tissue on the interior. (6)
There were 530,000 tonsillectomies (with or without adenoidectomy) performed on
children under fifteen in 2006; although this number is less than it once was (1.4 million in
1959), the prevalence of the procedure has increased in recent years (315,000 in 1996).
(25) Indications for tonsillectomy have shifted over time. The most common current
indication is hypertrophied tonsillar tissue that causes upper airway obstruction “sleepdisordered breathing.” Symptoms and signs can include snoring and sleep fragmentation,
leading to daytime exhaustion, with possible effects on behavior and/or school
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performance.

Obstructive sleep apnea (OSA) is diagnosed when there is a complete

blockage of the airway during sleep and intermittent hypopnea, leading to hypercarbia and
hypoxia; the gold standard for diagnosis of OSA is overnight polysomnography. (6) Recent
studies have also shown activation of inflammatory pathways as a result of sleep disordered
breathing, including activation of cytokine cascades. (26) Adenotonsillectomy is a well
proven intervention for sleep disordered breathing in children. (27)
Recurrent or persistent pharyngitis is the second most common indication. Classic
studies have used as criteria for tonsillectomy: 7 infections in one year, 5 in two years, 9 in
three years, or chronic tonsillitis defined as sore throat lasting for at least 3 months. (28)
Studies have shown there to be a benefit from adenotonsillectomy in reducing the number
of infections; however, the improvement in a recent meta-analysis was not dramatic. (29)
The exact role of tonsillectomy as therapy for recurrent pharyngitis remains somewhat
controversial.
Other less common indications include peritonsillar abscess unresponsive to
medical therapy and, rarely, suspected malignancy. (6, 28)
The “one-airway hypothesis” suggests that abnormally inflamed tonsillar tissue,
whether due to infection or due to hypertrophy and causing sleep disordered breathing,
may contribute to upper airway inflammation that is reflected in the lower airways and
thus may contribute to asthma. Studies report conflicting results on the relationship
between obstructive sleep apnea and asthma; though studies outside of the U.S. report
asthma as a risk factor for a diagnosis of OSA (30), one U.S. study found that asthma was not
a risk factor and in fact parental report of asthma decreased the risk of an OSA diagnosis.
(31) Nonetheless, it is possible that the hypertrophied or inflamed tonsillar lymphoid tissue
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chronically or intermittently triggers airway inflammation and asthma; removing the
tonsils would eliminate this trigger.
A handful of observational studies support this concept. (7)

One early study

demonstrated that up to 88% of patients with asthma experience a significant improvement
in symptoms and reduce or eliminate asthma controller or rescue medication usage
following adenotonsillectomy.(8) A recent retrospective chart review of 93 children with
asthma who underwent tonsillectomy for standard indications showed significant
improvements in multiple asthma measures including mean hospital visits, systemic steroid
administration, asthma medication use, and childhood asthma control test scores.(9) In
addition, a recent cohort study identified children with poorly-controlled asthma and
referred them for polysomnography; if diagnosed with OSA, the children were offered
adenotonsillectomy.

Post-tonsillectomy data for 35 children showed a significant

improvement from adenotonsillectomy in asthma control, defined by asthma exacerbations,
weekly rescue medication usage, asthma symptom score, and FEV1.(10) Limitations of the
study include lack of control groups (non-surgical, well-controlled asthma, non-asthmatics),
a study design that included identification of OSA as “part of clinical routine”, loss to followup, and lack of time frame indicated. (32)
Whether or not this reported improvement is a purely clinical effect on the airway,
or is a biological effect on airway inflammation and asthmatic pathogensis, has not yet been
studied.
Chitinases in Asthma
Chitinases are a family of hydrolases detectable in the circulation that correlate with
inflammation and disease activity in a number of chronic diseases including asthma and
adenotonsillar disease. (33) These proteins bind to or cleave chitin, the second most
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abundant polysaccharide in nature and the major structural polymer in cell walls of bacteria
and fungi, the shells of crustaceans, and the exoskeletons of arthropods such as cockroaches
and dust mites, common allergic triggers in asthma. Animal models have shown that chitin
can have either pro- or anti- inflammatory effects – when delivered orally or intransally,
chitin inhibits Th2 inflammation; when delivered to the lung in isolation, chitin enhances
Th2 inflammation. These results suggest a complex interplay between environmental chitin
exposure and the pathogenesis of asthma. (33, 34)
Though mammals do not have chitin, they have conserved chitinase proteins that
break down chitin from the environment. Like chitin itself, there is evidence in animal
models as well as humans that chitinase proteins can act as up- or down-regulators of the
innate immune response by interacting with and degrading chitin and by modulating the
host’s inflammatory response. Chitinases may act as the link between environmental chitin
exposure and the Th2 inflammatory response. (33, 35) There are two major chitinases in
humans; chitotriosidase (CHIT1) is a true enzyme with the ability to hydrolyze chitin, while
YKL-40 (CHI3L1) is a chitinase-like protein, which has the ability to bind to chitin but not to
degrade it. Both chitinase activity and YKL-40 levels are demonstrated to be elevated in the
bronchoalveolar lavage fluid of children with asthma. (36)
Chitotriosidase has been shown to be the primary active chitinase enzyme in the
human lung. (37) It also is the only active chitinase in the peripheral blood, meaning that
measurement of serum chitinase activity is a surrogate for measurement of chitotriosidase
levels. Serum chitinase activity has been shown to be elevated in a number of disease states,
including Gaucher’s disease, thalassemias, arteriosclerosis, and coronary artery disease. It
is elevated in the bronchoalveolar lavage fluid in certain lung diseases including sarcoidosis
and interstitial pulmonary fibrosis. (33)
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Chitotriosidase is overexpressed in adenoid tissue of children undergoing
adenotonsillectomy with concurrent chronic rhinosinusitis, otitis media with effusion, and
allergic rhinitis compared to subjects without concomitant upper airway disease. (38)
Proteins in the chitinase family have also been demonstrated as markers of the
systemic component of asthmatic disease. A cross-sectional study of children with allergic
and non-allergic asthma showed that chitotriosidase levels were elevated in the serum of
individuals with asthma children versus control subjects. (39) YKL-40, the chitinase-like
protein, has been reported to be elevated in the serum of individuals with asthma and levels
correlate positively with disease severity. Specifically, Chupp et al. showed that levels
correlated with poor pulmonary function tests, subepitithelial basement membrane
thickening, and airway remodeling in the Paris cohort. (40) Members of the chitinase
family may reflect a biological link between upper airway inflammation alleviated by
adenotonsillectomy and the effect of environmental triggers in the pathogenesis of asthma.
Chitinase Genetics
Studies have shown mixed results on the role of genotypes for chitinase proteins on
asthma. CHIT1, the gene encoding chitotriosidase, has a polymorphism containing a 24base pair duplication in exon 10 (rs3831317) that produces a non-functional protein. The
allele is highest frequency in East Asian, Middle Eastern, and Indian populations. (33) Lee
et al. reported associations between the 24-bp duplication and positive TB tests in
Europeans but not in Asians, and an association with three or more atopic diseases (asthma,
allergic rhinitis, atopic dermatitis, allergies to drugs, cosmetics or food, and frequent
sneezing, watering, or nasal congestion) in Asians but not in Europeans. (41) Though
significant, the p-values were modest, the definition of atopy broad, and there were
differences among ethnic groups, raising the possibility of a false positive result. (33)
Vicencio et al. reported in an observational study 6 asthmatic pediatric patients with fungal

Levin et. al, 10
sensitization, all of whom had the CHIT1 24-bp duplication. (42) However, other larger
studies have reported no association between the allele and presence of asthmatic disease,
emergency room visits for asthma exacerbations, or hospitalizations due to asthma. (43, 44)
A stronger association between asthma and the genotype of CHI3L1, the gene
encoding YKL-40, has been reported.

CHI3L1 contains a promoter SNP (rs4950928,

131CG); the C allele (major allele) is associated with elevated YKL-40 levels. A study
looking at frequency of the SNP in a founder population of European descent (the
Hutterites) as well as multiple other case-control populations showed an association of the
C

allele

with

asthma

prevalence,

poor

pulmonary

function,

and

bronchial

hyperresponsiveness. (45) Cunningham et al., in a large cross-sectional study of pediatric
patients with asthma, showed that the G allele (minor allele) was protective for asthmarelated hospitalizations. (46) A study of Korean children demonstrated an association
between C haplotype and atopy, though there was no association with asthma. (47)
Gene Expression in Asthma
Gene expression profiling techniques allow for the high-throughput identification of
novel genes and pathways involved in disease pathogenesis. This technique has been
increasingly used in asthma to study its complex etiology. There exist a number of studies
looking at human tissue in asthmatics. (48)
A number of studies have examined bronchial biopsy tissue, as the principal tissue
affected in asthma. Liprase et al. used microarray technology to compare gene expression
from 4 subjects with mild asthma (who were not on ICSs) and control subjects. They found
that 20 genes were up-regulated and 54 genes were down regulated, including immune
signaling molecules, extracellular proteins, immune response proteins, and intracellular
signaling molecules. Some genes were identified that were known to be involved in asthma
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pathogenesis, including nitric oxide synthase 2A (NOS2A), glutathione peroxidase 3 (GPX3),
and T-cell receptor α (TCRα); others were newly implicated including arachidonate 15lipoxygenase (ALOX15), which may be involved in airway remodeling, and fractalkine
receptor (CX3CR1), previously found to be elevated in peripheral CD4+ lymphocytes of
asthmatics, serpin proteinase family inhibitors, some of which have been found to be
elevated in the serum of asthmatics. (49) Another study using RT-PCR of bronchial samples
confirmed a number of genes identified by Laprise et al. and also identified others, including
the Na+ K+ Cl- co-transporter (NKCC1) which showed eightfold increased expression in
asthmatics. (50) Woodruff et al. studied airway epithelial cells in adults with asthma in a
randomized trial of inhaled corticosteroids. A calcium-activated chloride channel (CLCA1),
periostin, and serine peptidase inhibitor B2 were up-regulated in asthmatics.
Corticosteroid therapy down-regulated expression of the three genes, and high baseline
expression of the three predicted improvement. (51) The limitation of bronchial studies is
that bronchial biopsy samples are often heterogeneous due to differing biopsy techniques
and patterns of disease. (48)
Other studies have looked at upper airway epithelial cells. Lilly et al. examined
individuals with mild asthma and subjected them to an allergen challenge. A number of
genes previously implicated in asthma were found to be differentially expressed genes
between pre- and post-challenge airway epithelium, including included IL-1β, IL-8, TNF-α
induced protein 6, lipocortin-1, and plasminogen activator inhibitor 2. (52) Guadajero et al.
recruited 10 children with stable asthma, 10 children experiencing an acute asthma
exacerbation, and 10 nonatopic children without asthma. They used a pooled microarray
analysis to compare expression profiles of nasal respiratory epithelial cells from each group.
37 immune-related genes were among the up-related genes in the acute-exacerbation
group, with 9 cilia-related genes consistently down-regulated. (53)

Limitations for
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epithelial studies include sample heterogeneity, questionable representation of the lower
airway in the nasal epithelia, and confounders including rhinitis and atopy. (48)
Given that asthma is a systemic disease, a number of studies have looked at
expression in circulating cells. Brutsche et al. examined peripheral blood mononuclear
cells. They developed gene expression based score (composite atopy gene expression, or
CAGE) to predict atopy with 96% sensitivity and 92% specificity; the score is based on the
expression of 10 genes including IL-1 receptor, IL-6, and the IFN-αβ receptor. Additionally,
a number of B-cell isotype, cell survival, and IgE production genes were up-regulated in
severe asthma. (54) Aoki et al. performed expression profiling of genes related to asthma
exacerbations in the peripheral blood mononuclear cells of children. They found during an
exacerbation 137 up-regulated and 16 down-regulated genes; 62 were also differentially
expressed during an upper respiratory infection. Many of these genes were related to
immune responses to external stimuli, supporting the notion that asthma exacerbations and
respiratory infections share a common mechanism. (55) In peripheral blood lymphocytes,
Hansel et al. found up-regulated genes in asthma to include TGF-β and genes involved in T
cell activation. (56) The involvement of TGF-β was confirmed by another microarray study
of CD4+ lymphocytes in asthmatics versus controls. (57)

Hypothesis and Aims
Asthma is a heterogeneous disease of the lower airways that remains a significant
healthcare concern for the pediatric population despite numerous public health and
pharmacologic advances to control the disease. Recent studies have shown a link between
upper airway inflammation and asthma, and respiratory infection and allergen exposure are
frequently indicated as triggers for asthma exacerbations in pediatric patients.
Adenotonsillectomy is common surgical procedure in children performed to address upper
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airway hypertrophy, infection, and inflammation. A number of observational studies have
demonstrated a positive clinical effect of this surgery on asthma control; however these
studies have limitations due to study design, and no previous studies have examined the
effect of adenotonsillectomy on biomarkers on inflammation.

Chitinases have been

implicated in the pathogenesis of inflamed adenotonsillar tissue, and in the presence and
severity of asthma, and may reflect a biological link between upper airway inflammation
alleviated by adenotonsillectomy and the effect of environmental triggers in the
pathogenesis of asthma. Gene expression profiling in the blood and upper airway tissue of
patients undergoing adenotonsillectomy may be able to characterize biological changes due
to the procedure and identify genes uniquely affected in children with asthma undergoing
the procedure.
We hypothesize that asthmatic control will improve in children undergoing
adenotonsillectomy. Using chitinase levels and gene expression profile data in the serum
and upper airway, we postulate it is possible to characterize unique biological changes
among children with improvement in asthma control undergoing the surgery compared to
children without improvement and children without asthma.
Specific Aims
1. Conduct a prospective observational study of pediatric patients, with and without
asthma, undergoing tonsillectomy for standard indications.

Asthma will be

characterized by clinical symptoms and pulmonary function tests.

Serum

biomarkers including chitotriosidase activity, YKL-40 levels, and IgE will be
measured, and expression profile data of tonsillar tissue, nasal epithelium, and
peripheral blood will be collected.

Questions, PFTs, serum biomarkers, and

peripheral blood expression data will be repeated 6 months post-operatively.
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2. Compare asthma control pre- and post-operatively, and retrospectively identify any
clinical characteristics pre-operatively that predict a positive outcome.
3. Determine the changes in chitotriosidase activity, YKL-40 levels, and genetic
expression profiles pre- and post-operatively of asthmatics and non-asthmatics
undergoing tonsillectomy.

CHIT1 and CHI3L1 genotypes will be determined at

baseline.
4. Correlate clinical findings (in Aim 2) with biomarker and genetic findings (in Aim 3)
to determine if there is (a) a characteristic biological response in patients who see
symptom improvement after tonsillectomy and (b) a set of biomarkers that could be
measured pre-operatively that would predict clinical improvement after operative
intervention.

Methods
Enrollment and Follow-up
Pediatric patients ages 2-18, with and without asthma, who were undergoing
adenotonsillectomy for standard indications at Yale New Haven Children’s Hospital and

North Haven Surgery Center were recruited over a 13-month period. Informed parental
consent and child assent for patients age ≥ 7 were obtained. All procedures were approved
by the Yale University and the Yale New Haven Hospital Human Investigation Committee.
On the day of surgery, a study member administered a questionnaire to the subject’s
parent. Definition of asthma was based on a previous physician diagnosis prior to surgery.
The questionnaire consists of pulmonary history, including history of asthmatic disease; a
list of common triggers with examples including infection, allergy, household (dust, smoke,
carpet), environment (pollution, cold weather), and exercise; Emergency Department (ED)
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or urgent care visits related to asthma; steroid courses; comorbidities including history of
sinus disease, gastroesophageal reflux disease (GERD), allergic rhinitis, and eczema;
medications, including compliance, perception, and frequency of usage in the last 4 weeks;
and days of school missed and parental days of work missed due to the child’s asthma and
other illnesses.

Subjects with asthma also completed an age-appropriate version of the

Asthma Control Test (ACT), with the assistance of parents or guardians as needed. (22, 23)
Adult ACT scores were rescaled from maximum 25 to 27 in order to compare to childhood
ACT scores, which also have a maximum score of 27. Children were defined as having
poorly-controlled asthma at baseline by one of the following criteria, based on asthma and
ACT guidelines: pediatric or adult ACT < 20, two or more ED/urgent care visits in the
previous year, two or more oral corticosteroid courses in the previous year, or using SABA
medication more than twice per week in the last month. (21) Children age six and above
completed Pulmonary Function Testing (PFTs) if they were able to comply with the
instructions given. Intraoperatively, the anesthesiology team obtained venous blood in
serum.
Six months after surgery, parents were contacted by telephone or email. Primary
study outcome for children with asthma was measured by retesting an ACT score. The
follow-up questionnaire was also administered to parents, with rates calculated for
variables measuring number of incidences over a given time (Emergency/Urgent Care
visits, steroid courses, school and work days missed). Changes were used to calculate a
composite variable of improvement in asthma control, with improvement defined as one of
the following: increase in ACT score of 3 or greater, decreased rate of Emergency/Urgent
Care visits, a decreased rate of oral corticosteroid courses, or a decrease in rescue short
acting bronchodilator (SABA) usage in the previous month. PFTs were also repeated for
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those study subjects with initial testing. Repeat blood samples were drawn at this time as
well. Study participants were compensated for completing follow-up.
Chitotriosidase Activity, YKL-40 levels, and IgE levels
Serum chitinase activity was determined using a fluorimetric assay as previously
described, and reported as nmol/mL/hr. (37, 58) Briefly, 44 µmol/L substrate was prepared by
mixing 1 mg 4-methylumbelliferyl-β-D-N,N’,N’’-triacetylchiotrioside in 2mL H2O and 26.9
mL of McIlvain buffer, then sonicated and incubated at 37°C until dissolved. Serum was
immediately spun down at 1500rpm for 10 min after collection; the supernatant was
extracted and stored at -20°C. To measure the enzyme activity, 180µL substrate was mixed
with 20µL serum. The mixture was incubated at 37°C for 30 minutes. 2mL Stop Solution
(0.3mol/L glycine-NaOH, pH 10.6) was added to each sample, and then each sample was
measured using fluorometry (Sequioa Turner).

Enzyme activity was calculated in

nmol/mL*h using a standard curve.
YKL-40 levels were determined using commercially available enzyme-linked
immunosorbent assay (ELISA) kits (MicroVue), as previously described. (40). Briefly, serum
from each subject was measured in duplicate. 100 µL capture solution was added to 20 µL
of each sample in plates included with the kit. After 1 hour incubation at room temperature,
sample wells were emptied and then washed three times with 300 µL wash buffer. 100 µL
enzyme conjugate was then added to each well. Samples were incubated for another hour
at room temperature, followed by three more washes. 100 µL substrate buffer was then
added to each well. After incubation for 1 hour at room temperature, 100 µL stop solution
was added to each sample. Levels were measured by plate reader (BioTek) based on a
standard curve. Median values between sample duplicates are presented. If measured
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levels between the duplicates showed a more than 30% discordance, the sample was
repeated.
IgE levels were measured by commercially available services (Healthpoint
Diagnostix, Inc).
Genotyping
We extracted DNA from blood using the QuickGene DNA whole blood extraction kit
(Fujifilm). Briefly, blood was stored in Solution A tubes and immediately refrigerated at
4°C. 300 µL protease and 2.5 mL lysis buffer were added to each 2 mL blood, and the
samples were incubated 30-40 minutes at 56°C.

2.5 mL 100% EtOH was added to

neutralize the lysis buffer, and then the DNA was extracted using the QuickGene system.
The concentration of DNA was confirmed using the NanoDrop spectrophotometry system.
We examined the prevalence of a promoter SNP in the CHI3L1 gene encoding YKL40, rs4950928 (131 CG). The C allele has been shown to be associated with elevated
levels of YKL-40. The SNP was genotyped with differentially labeled primers containing the
C and G allele using TaqMan q-PCR Assay-on-Demand (ABI). Briefly, 1 µL of sample DNA
was added to an Assay Mix that included the labeled rs4950928 primers, dNTPs, and
enzyme.

After the PCR reaction was complete, each sample was scanned (Applied

Biosystems 7500 Fast Real Time-PCR); based on the incorporated label, each sample was
identified as having the C or G SNP. (45)
We also examined the prevalence of the 24-bp exon 10 duplication in the CHIT1
gene encoding chitotriosidase. The duplication results in a nonfunctional protein. We
performed PCR on the DNA using primers for exon 10; the duplication genotype was
differentiated from the wild-type using gel electrophoresis. Briefly, 1 µL of sample DNA and
exon 10 primers were added to premixed solutions with dNTPs and polymerase. After the
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PCR reaction was complete, gel electrophoresis was performed; based on segment length,
each sample was determined to either be wild-type or include the duplication.
Statistical Analysis
All clinical and experimental data was uploaded onto the Yale Center for Asthma
and Airway Diseases online database. Statistical analyses were performed using IBM SPSS
Statistics version 19. Nominal data was compared using Fisher’s Exact test and Pearson’s
chi-square; all scaled data was confirmed to be of a non-normal distribution with the
Shapiro-Wilk test for normality; thus, non-parametric methods including Mann-Whitney U
and Wilcoxon Signed Rank Tests were employed. p-values <0.05 were considered
significant.
RNA Extraction
Tonsillar and nasal epithelial tissue were immediately stored in 500 µL RNALater™
(Invitrogen) solution and refrigerated at 4°C overnight to allow for the solution to permeate
the tissue, then stored long term at -80°C.
To extract DNA from tonsillar tissue, 50-100 mg sample was cut and transferred to a
fresh 14mL Falcon tube. 1 mL Trizol solution (Invitrogen) was added. The sample was
homogenized using sonication for 30 seconds, with 15 second PBS washes of the sonication
probe between samples. The homogenized mixture was then transferred to a 1.5 mL
centrifugation tube. The solution was spun down at 12000g x 10 min at 4°C, and then
incubated at room temperature for 5 minutes. 750 µL supernatant (aqueous phase) was
extracted; 150 µL chloroform was added. After vortexing to mix, the sample was set to
incubate at room temperature for 3 minutes. Afterwards, it was spun down again at 12000g
x 15 min at 4°C. At this point, 300 µL supernatant was transferred to a DNA column from
the RNA Easy Mini Plus Kit (Qiagen).
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The DNA column was spun at 10000 rpm x 30 sec at room temperature. Flow
through was collected and the column discarded. 300 µL (1:1 volume) 70% EtOH was
added to the flow through and mixed well by pipetting. This solution was transferred to the
RNA Column from the kit. It was spun at 10000 rpm x 30 sec at room temperature. With the
RNA in the column, the flow through was discarded. 700 µL RW1 Wash Buffer was added
and spun down at 10000 rpm x 30 sec; another two washes were completed with 500 µL
RPE Wash Buffer and spun down at 10000 rpm x 30 sec; this was followed by a dry spin of
10000 rpm x 2 min. Lastly, 50 µL water was added to the column and spun down at 10000
rpm x 1 minute to elute the RNA. The presence of RNA and concentration was measured
using the NanoDrop spectrophotometer; if more concentration was desired, the 50 µL
elution was re-spun through the column for a higher RNA yield.
This method was a modification over previously attempted methods to isolate the
RNA using Trizol solution (Invitrogen). At first, samples were stored in Trizol. RNA was
extracted after homogenization, separation of the aqueous phase once chloroform was
added, and then purified by spinning down to create an RNA pellet. However, it was found
that despite good concentration, RINs (RNA Integrity Numbers) were poor, indicating RNA
degradation. This method was modified to use the Qiagen RNA Easy Mini Plus Kit for
column purification of the RNA, rather than using an RNA pellet, but RINs were still poor.
Finally, RNALater™ was used instead of Trizol as the storage solution for the tissue samples.
This drastically improved RINs, though there was found to be some protein contamination
(low A260/A230, as measured by NanoDrop). The final modification to create the protocol
as listed above, was adding an extra spin down step after homogenization but before adding
chloroform to remove insoluble protein precipitate from the Trizol mixture before
separation of layers.

This procedure allowed us to consistently produce high

concentrations of high quality RNA from tonsillar samples. However, the first 60 tonsillar
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samples collected were stored in Trizol and therefore have low quality RNA that was not
used in expression analysis.
A similar process was employed to extract RNA from nasal epithelial tissue. Again,
tissue was stored in 500 µL of RNALater™, and refrigerated at 4°C for one night before long
term storage in -80°C. Preparation for extraction included mixing 3.5 µL β-mercaptoethanol
and 350 µL RLT buffer (Qiagen RNA Easy Mini Plus Kit). The nasal swab brush was then
transferred from the RNALater™ to the RLT buffer with β-mercaptoethanol and allowed to
sit on ice for 30 minutes. After incubation, the mixture, with the swab, was vortexed for at
least 15 seconds. The solution was then transferred to a QIAShredder column. Finally, the
original tube with the swab was spun at low speed for 1 min, and any remaining solution
was added to the QIAShredder column. The QIAShredder was spun at 10000rpm x 2min;
flow through was transferred to the DNA column and the procedure was carried out with
the Qiagen RNA Easy Mini plus Kit, exactly as stated above for the tonsillar tissue RNA
extraction. Again, this method was a modification after samples that were stored in Trizol
produced low RIN numbers. The first 60 samples collected were stored in Trizol and
therefore have low quality epithelial RNA.
To extract RNA from whole blood, peripheral blood was collected in a Tempus™
tube (Applied Biosystems) and stored at -20°C. It was found to be important that the blood
was mixed well with the solution in the Tempus™ tube immediately after collection to
ensure RNA preservation. To extract the blood RNA, 3 mL PBS and the peripheral blood
were mixed and vortexed, then spun at 3000g x 30 minutes at 4°C. The supernatant was
discarded after the spin (though kept in case RNA extraction failed and needed to be
repeated). Tubes were air dried, facing upside down on a paper towel for 5 minutes, then
dried with a cotton swab (being careful not to swab the bottom of the tube, the location of
the RNA pellet). Using the Total RNA Purification Kit (Norgen), 400 µL Lyse Buffer was

Levin et. al, 21
added to each sample and vortexed. 200 µL 100% EtOH was added and mixed by pipetting.
The solution was then transferred to the Norgen RNA extraction columns. Samples were
centrifuged at 13000 rpm x 1min at room temperature. The flow through was discarded.
Each sample was washed three times with 400 µL Wash Buffer, 13000 rpm x 1 min for the
first two washes and 13000 rpm x 3 min for the last wash. After a dry spin of 13000 rpm x
2 min, 50 µL Elution buffer was added. The sample was let to sit for 1-2 minutes, and then
spun at 13000 rpm x 2 min.
Extracted RNA from all tissue types was sent to the Keck Laboratory on the Yale
West Campus, where RNA quality was measured by looking at the integrity of 18S and 28S
ribosomal RNA. Their integrity indicated good sample quality; their absence reflected RNA
degradation in the sample. The computer generated an RNA Integrity Number (RIN) for
each sample based on the 18S and 28S rRNA integrity; RINs ≥ 6 were generally considered
acceptable; however if spectrophotometric peaks for the 18S and 28S rRNA looked
acceptable to the eye but the computer calculated a low RIN or could not calculate a RIN, the
sample was also included.
Microarray Analysis
Affymetrix™ Gene Chip Human Exon 1.0 ST microarrays were used for analysis.
Gene Chip Human Exon 1.0 ST Arrays contain 5,362,207 features with 1.4 million probesets
that cover over one million exon clusters, 289,961 known genes by mRNA transcript, and
665,175 genes by Expressed Sequence Tags.

The Keck Laboratory performed all

microarray readings according to Affymetrix protocols. Blood samples were cleaned of
hemoglobin prior to reading. All samples underwent cDNA amplification using PCR prior to
read.
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Scanned output files were analyzed using Affymetrix™ software, and cell image data
files were loaded into GeneSpring GX software version 11 (Agilent).

Data were log-

transformed, normalized, and baseline-converted was performed to median values by RMS
for each individual analysis group (tonsil samples, nasal epithelial samples, baseline blood
samples, and matched baseline & follow-up blood samples) Quality control on each set was
performed using PCA plot.

Interpretations were performed for baseline blood, nasal

epithelium, and tonsil samples according to improvement in asthma control. Differential
gene expression was determined by t-test; genes for analysis were limited to differential
expression p<.05 and fold change > 1.5. No post hoc testing for multiple comparisons,
including Benjamini-Hochberg method, was used due to insufficient results after
corrections.

Interpretations for improved control, not improved control, and control

subjects were also performed on matched baseline and follow-up blood samples;
differential gene expression was determined by paired t-test without post hoc testing for
multiple comparisons; again, genes for analysis were limited to differential expression
p<.05 and fold change >1.5.

Gene Ontology categories and pathways that were well

represented among the gene lists were determined, with p < 0.1. (53, 59) Individual genes
were searched for relevance in the NCBI Gene databases.

Results
Cohort Characteristics
130 patients total undergoing adenotonsillectomy were enrolled, ages 2-18, over a
13 month period. 66 subjects had diagnoses of asthma; 64 subjects were controls (Figure
1). 75% of study participants had a primary indication of tonsillar hypertrophy, including
symptoms of sleep-disordered breathing, for surgery. 23% of participants had a primary
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indication of recurrent tonsillitis/infection for surgery; there was no significant difference
between asthma and control groups. Compared to controls, children with asthma had
higher incidence of expected comorbidities including atopy (seasonal allergies and/or
eczema) and a history of GERD, and were more common of Hispanic origin (p=0.01, 0.01,
0.03, respectively). (60)

Children with asthma had a lower median FEV1 (p=0.03),

consistent with a physician diagnosis of asthma (Table A). Baseline ACT scores ranged from
6-27, with a median of 22 (interquartile range 16-22). 46 children completed the pediatric
ACT and another 5 children completed the adult ACT at baseline; 15 children never
completed a baseline ACT. 29 subjects were administered ACT questionnaires following
surgery during the follow-up period, rather than prior to surgery. These families completed
the ACT prior to follow-up by phone or at the follow-up appointment. There was no
relation between indication for surgery and baseline ACT score. 38 out of 66 (58%) had
poorly-controlled asthma (ACT < 20, ≥ 2 ED/urgent care visits in the previous year, ≥ 2 oral
corticosteroid courses in the previous year, or using SABA medication more than twice per
week in the last month).
Follow-up was achieved in 81% of the enrolled subjects (N=105), 58 subjects with
asthma and 47 control subjects. Bloodwork was obtained for 122 participants (94%) at
baseline; 67 parents gave consent (64% of those achieving follow-up) to have bloodwork
performed post-operatively. Patients were primarily lost to follow-up due to failure to
respond or unable to contact (moved or changed phone number). Mean time to follow up
was 7.0 months (range 5-12, SD 1.5), and was not statistically different between study
groups. Follow-up rate was also not statistically different for patient age, gender, race,
ethnicity, or indication for tonsillectomy.
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Effect of Adenotonsillectomy on Asthma Control
Asthma control and asthma-related healthcare utilization were significantly
improved after adenotonsillectomy. There was a clinically significant improvement in ACT
scores after 6 months (median increase from 22 to 25, p< 0.001, Figure 2a) and subjects
with asthma reported significant decreases in the rate of ED/Urgent Care visits, oral
corticosteroid courses, missed school days due to asthma, and total missed parental work
days due to illness (Table B).

An improvement in score of 3 or more was considered

clinically significant, previously shown to be the minimally important difference in score.
(24) Of 35 individuals with rescaled ACT scores < 25, 24 subjects (69%) had increases in
score of 3 or more (p< 0.001, Figure 2b). 12 of 27 children (44%) on controller medications
for asthma at baseline were no longer on controller medication at follow-up. Two children
“developed” asthma during the follow-up period; these children were characterized as
controls since they were classified as without asthma at the time of surgery. PFT scores did
not significantly change for either study group between baseline and follow-up. Subgroup
analysis of children with poorly-controlled asthma at baseline demonstrated a more
pronounced increase in ACT score, from a median of 18 to 24. (21)
The composite variable of improvement in asthma control was defined by fulfilling
one of the following categories: increase in ACT score of 3 or greater, decreased rate of
Emergency/Urgent Care visits, a decreased rate of oral corticosteroid courses, or a decrease
in rescue short acting bronchodilator (SABA) usage in the previous month. Of the 48
children with asthma who were not already maximally controlled at baseline, and therefore
had room to improve (pediatric ACT <25, adult ACT <23, one or more ED/urgent care visit
in the previous year, one or more oral corticosteroid course in the last year, or using SABA
medication in the last month), 36 (75%) had an improvement in symptoms in at least one
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category. When limited to the 34 subjects with poorly-controlled asthma at baseline, 29
(85%) had an improvement in symptoms in at least one category.
Improvement in asthma control, using the composite variable, did not significantly
correlate with baseline patient characteristics including age, years since asthma diagnosis,
comorbidities, smoke exposure, indication for adenotonsillectomy, or PFTs.

In the

subgroup analysis of children with poorly-controlled asthma at baseline, asthma control in
all 19 subjects who listed “Environment” as a trigger improved, while control in only 10 of
15 (67%) of those who did not improve (p=0.01). Improvement in control was also
significantly associated with a lower baseline ACT score among those with poor control at
baseline (median score of 22 for subjects with improved asthma control versus score of 16
for those without improved control, p< 0.05).
Analysis of Chitinase Genotypes and Levels
Genotypic analysis of the CHIT1 24-bp exon 10-duplication showed a significantly
higher allele frequency of the mutation in the asthmatic population undergoing
adenotonsillectomy, 26% vs. 14%, (t-test p< 0.02, Figure 3).

Analysis of the CHI3L1

rs4950928 (131 CG) promoter SNP showed a lower allele frequency of the minor G allele
in the asthma populations (14% vs. 18%, respectively), a result consistent with previous
findings though not significant in this study (p=0.39). Of note, CHIT1 and CHI3L1 genotypes
did not significantly associate with gender, race, or ethnicity. CHIT1 and CHI3L1 genotypes
also did not significantly associate with improvement in asthma control following surgery.
Chitinase activity was evaluated at baseline and follow-up. Corresponding to the
increased prevalence of the exon 10-duplication in children with asthma, chitinase activity
was significantly lower in the asthmatic population, median 3.1 nM/ml*hr (interquartile
range 1.9-5.3) vs. 3.9 nM/ml*hr for controls (interquartile range 3.0-6.6), (p< 0.01, Figure
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4a). While there was a significant decrease in circulating chitinase activity in children with
asthma (median decrease 0.4 nM/ml*hr, p< 0.01), there was no significant change in
chitinase activity in the control subjects after surgery (median no change, p=0.83). Within
the asthma group, chitinase activity significantly decreased in subjects with improved
control (p=0.001), while it was unchanged in those who did not improve (p=0.73, Figure
4b). Baseline chitinase activity was also significantly higher in subjects whose asthma
control improved versus those whose control did not, median 3.5 nM/ml*hr (interquartile
range 2.6-6.6) versus 2.2 nM/ml*hr (interquartile range 1.4-3.5) nM/ml*hr, p< 0.01). YKL40 levels were higher among children with asthma (median 41.5 ng/mL versus 35.5 ng/mL ,
interquartile ranges 27.5-62.4 versus 25.8-50.1), but this was result was not statistically
significant (Figure 4a). This trend corresponded to the lower prevalence in the asthmatic
population of the promoter SNP 131 GC, which increases YKL-40 expression. YKL-40
levels not change significantly in either study group over the study period (Figure 4c).
Improvement in asthma control did not correlate with baseline YKL-40 level, change in
YKL-40 level over the study period, or baseline IgE levels.
In the subgroup analysis of children with poorly-controlled asthmatic subjects at
baseline, the decrease in chitinase activity remained statistically significant when disease
activity asthma control improved (median decrease 0.9 nM/ml*hr, p< 0.01), but not when
disease activity control remained unchanged (median no change, p=1.00), as defined by the
composite variable (Figure 4d). In this subgroup, baseline chitinase activity was again
significantly higher in asthmatic subjects whose asthma control improved versus those
whose asthma control did not (median 3.4 versus 1.9 nM/ml*hr, interquartile ranges 2.45.4 versus 0.8-3.0, p< 0.05). A baseline chitinase activity ≥ 2.35 predicted improvement
with 82% sensitivity and 80% specificity among children with poorly-controlled asthma.
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Gene Expression Analysis
In nasal epithelial samples, 46 exon clusters including 32 known genes were
differentially expressed among children with asthma between those with improved control
and those without(unadjusted p<0.05, |Fold change (FC)|>1.5, Table C).

Using NCBI

databases, transcripts related to asthma, the upper airway, or the inflammatory response
were identified.

Serpin Peptidase inhibitor B2 (SerpinB2), previously associated with

asthma, was down-regulated in the nasal epithelium of children with asthma with improved
control versus those without improved control (p<0.01, FC -1.96). It was also downregulated in children with improved asthma versus control subjects (p=0.03, FC -1.61).
Other inflammatory-related genes with differential expression in the nasal epithelium of
children with improved control versus those without improved control included two
glutathione S-transferases (GSTM1, p=0.03, FC -2.45; and GSTM4, p<0.01, FC -1.51) and IGF
binding protein 2 (IGFBP2, p=0.01, FC -1.50), which were down-regulated at baseline among
children with improved control.

A leukocyte immunoglobulin-like receptor (LILRB4,

p=0.04, FC 1.5), cytolysis protein perforin 1 (PRF1, p=0.02, FC 1.52), and a GTPase involving
T-cell survival (GIMAP5, p=0.02, FC 1.66) were up-regulated in baseline nasal epithelium
among children with improved asthma control. None of the above, aside from SerpinB2,
was differentially expressed in children with improved asthma versus control subjects.
In baseline blood samples, 7 exon clusters including 5 known genes were
differentially expressed (Table C); these included an interferon induced protein (interferoninduced protein with tetratricopeptide repeats 1-like protein - IFIT1L, p=0.02, FC -1.51) and
a carboxypeptidase produced by mast cells (CPA3, p<0.001, FC -1.51) which were both
down-regulated at baseline among children with improved control. Interestingly, IFIT1 (not
IFIT1L) was up-regulated in the blood of children with improved asthma control versus
control subjects. In tonsil tissue, 9 differentially expressed clusters and 7 known genes
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were identified, interestingly all of which are on the Y chromosome; none were
differentially expressed compared to control subjects (Table C).
In matched blood samples using pairwise comparisons (Table D), expression of
SerpinB2 decreased from baseline to follow-up in children with asthma that improved
(p<0.01, FC -1.54), but not in children with asthma that did not improve or in control
patients. This was the only differentially expressed gene among all children with improved
asthma; when limited to asthma that was poorly controlled at baseline, 25 exon clusters
with 15 known genes were differentially expressed.

These included SerpinB2, which

decreased in expression (p=0.01, FC -1.6), as well as interferon induced protein (IFIT1,
p=0.02, FC 2.27), HERC5 (p=0.04, FC 2.07), CD274 (p=0.04, FC 1.69), LAMP3 (associated with
Influenza A, p<0.05, FC 1.6), and an olfactory receptor (OR2W3, p=0.04, FC 1.52) which all
increased in expression.

None of these significantly changed in expression in either

children with asthma whose control did not improve or control subjects.

In control

subjects, 29 known genes showed differential expression pre- and post-operatively,
including interleukin 1B (IL1B, p=0.03, FC 1.53), cyclooxygenase-2 (PTGS2, the inducible
form, p=0.03, FC 1.5), adrenomedullin (ADM, p=0.04, FC 1.66), and free fatty acid receptor 2
(FFAR2 or GPR43, p=0.03, FC 1.64), all of which increased in expression. Granzyme to
eliminate transformed and virus-infected cells (GZMH, p=0.04, FC -1.65) and NK cell lectin
receptor (KLRF1, p=0.03, FC -1.65) both decreased in expression over the study period.
Gene Ontology analysis of differentially expressed genes between children with
improved asthma control versus those without improved control demonstrated significance
(p<0.1) in the baseline nasal epithelium for the classes of pathogenesis (p<0.01), MHC Class
II protein complex (p<0.01), and membrane parts (p=0.08). In the baseline blood samples,
serine-type endopeptidase inhibitor activity (p<0.05) was the only significant class.
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Discussion
Though a number of observational studies have demonstrated a positive clinical
effect of adenotonsillectomy on asthma control, these studies have contained limitations in
size and study design. (32) No study to our knowledge has examined the effect of
adenostonsillectomy on markers of airway inflammation; we chose to explore chitinases
given previous, separate findings liking them to both asthma and adenotonsillectomy. (38,
40) In this study, we have demonstrated that asthma control and healthcare utilization
significantly improve after adenotonsillectomy and that this improvement is associated
with a decrease in chitinase activity in the circulation that is not evident in children without
asthma. Therefore, while this procedure has effects on upper airway inflammation and
mechanics that contributes to improved asthma control, these results suggest that
adenotonsillectomy also modulates airway inflammation in asthma.
This longitudinal, observational study followed children with asthma undergoing
adenotonsillectomy for standard clinical indications, using both clinical and biological
characterizations. We used a past physician diagnosis of asthma as our identification
criteria, which was supported by the statistically lower %FEV1 in the asthmatic group. The
asthmatic group also had statistically more children of Hispanic or Latino heritage;
however, this did not significantly correlate with chitinase activity or YKL-40 levels. A six
month follow-up was chosen to minimize any natural changes of asthma control with age,
but to provide enough time to see clinical and biological changes in airway inflammation.
The study demonstrated that a vast majority of subjects with asthma undergoing
adenotonsillectomy reported improvement in symptoms after 6 months.

75% of all

children with asthma not already maximally controlled at baseline, and therefore with room
to improve, reported symptom improvement. 85% of children with poorly-controlled
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asthma at baseline reported improvement. Response was significantly associated with a
lower baseline ACT score, indicating that those with poorly-controlled asthma were most
likely to see a benefit from the surgery, and listing environmental exposures as a trigger
(including exposures outside the home, weather changes, and pollution).
ACT score, a validated tool to monitor asthma symptoms and severity, increased on
average over 3 points from baseline to post-operative follow-up. An initial group of 29
subjects with asthma enrolled in the study had baseline scores collected after the
procedure; median baseline ACT score in this group was identical to baseline ACT scores
collected pre-operatively (score of 22), and thus, all scores were included in analysis.
A strength of this study is that we have identified a serum biological marker,
chitinase activity, which decreases with improvement in asthma after adenotonsillectomy
but does not change in subjects without asthma undergoing the procedure. Given the
difficulties of performing a randomized controlled trial of surgery for pediatric asthma
patients, identifying positive clinical and biological predictors for symptom improvement
would help to categorize patients most likely to benefit from adenotonsillectomy and
further justify a biological effect of the surgery on asthmatic inflammation. Higher serum
chitinase activity was also significantly associated with improvement in disease activity in
both the entire cohort of individuals with asthma as well as the subgroup with poorlycontrolled asthma at baseline. This data suggest that the surgery improves not only clinical
asthma symptoms, but also has a biological effect on inflammation associated with asthma.
Genotype analysis of our baseline population showed a higher prevalence of the
CHIT1 24-bp exon 10 duplication in children with asthma who were undergoing
adenotonsillectomy. Correspondingly, baseline chitinase activity was significantly lower in
this population.

These results are somewhat surprising since chitinase activity also
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decreased in children whose asthma control improved following the procedure, and
genotype did not associate with improvement. One possibility is differences in genetic
predisposition versus a response to an environmental effect (Figure 5). Specifically, our
data suggest that among children with tonsillar disease requiring adenotonsillectomy,
children with the mutation are more likely to have asthma, due to an inherently decreased
ability to modulate the effect of environmental substances on the airway (including chitin),
potentially related to the tonsils. This may result in more inflammation in the airway and
the development of asthma. Because we only explored this in a population of children with
tonsillar pathology, these conclusions cannot be applied to children with asthma as a whole.
The decline in chitinase activity following the surgery may represent an
environmental response rather than an inherent trait. The results suggest that in patients
who improve after adenotonsillectomy, tonsillar inflammation and hypertrophy may
contribute to inflammation of the lower airways. In accordance with the “one-airway
hypothesis,” removing the tonsils may reduce inflammation in the lower airway, decrease
chitinase activity, and improve asthma control. Those who do not improve control may
have different triggers or a distinct form of asthma, and thus chitinase levels are likely to
remain unchanged following the procedure in this group. Chitotriosidase has been shown
to have both pro-and anti-inflammatory properties. Whether the enzyme is responding to
inflammation in the airways induced in the environment as an attempt at negative feedback
or mediating the inflammation occurring in the airways cannot be discerned by this study.
While prior studies have demonstrated a strong association between serum YKL-40
and asthma severity (40), it was another chitinase family protein, chitotriosidase, whose
activity was found in this study to correlate with asthma and improvement in symptoms
after surgery. This distinction may be due to differences in the mechanism of chitin
response and Th2 inflammation in children and adults. Additionally, as CHIT1 expression is
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elevated in hypertrophied adenoid tissue of children with chronic upper airway and sinus
disease (38), chitotriosidase may play a unique role in airway inflammation triggered by
hypertrophied adenotonsillar tissue. A future direction will be to measure chitotriosidase
activity and YKL-40 levels in adenotonsillar tissue of children with and without asthma.
To our knowledge, global gene expression has never been studied in patients
undergoing adenotonsillectomy. This analysis demonstrated a number of relevant genes
that may act as biomarkers for changes in asthma control following to adenotonsillectomy.
The most promising is Serpin Peptidase inhibitor B2 (SerpinB2) since it has been implicated
in asthma previously, and it was differentially expressed in multiple compartments - blood
and nasal epithelial tissue.

Interestingly, SerpinB2 was downregulated in the nasal

epithelium among children whose asthma control improved versus children in which it did
not, and also decreased in expression in the blood from baseline to follow-up in children
that improved (but not in controls or children that did not improve). Serpin peptidase
inhibitor 2 inhibits tPA and uPA, thus preventing the activation of plasmin and promoting
fibrin formation. Its expression is provoked by IL-13. (51) Fibrinogen and thrombin
accumulation in the airways has been shown to be involved in airway hyperresponsiveness.
(61) SerpinB2 and carboxypeptidase A3, a mast cell product, were previously shown to be
up-regulated in genome wide profiling of asthmatic bronchial epithelium. (51) Response to
corticosteroids was associated with decreased expression of SerpinB2; likewise, in our
study serum expression of SerpinB2 decreased in children with improved asthma control
after adenotonsillectomy. Both higher SerpinB2 levels and carboxypeptidase A3 levels have
been shown, in separate studies, to predict response to corticosteroids. (62) However, we
identified that lower expression of SerpinB2 and carboxypeptidase A3 in the nasal
epithelium at baseline predicted improvement after surgery. This pattern may identify a
subgroup of children with asthma, possibly of a non-allergic type (given low levels of
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carboxypeptidase A3), unlikely to be controlled by conventional therapies and likely to
improve by adenotonsillectomy. Additionally, SerpinB2 knockout mice poorly regulate Th1
responses. (63) Thus, children with low baseline SerpinB2 levels may have an underlying
susceptibility to adenotonsillar-induced airway inflammation.
Glutathione S-transferases have also been implicated in asthma, and two (GSTM1
and GSTM4) were found to be down-regulated in the nasal epithelium of children whose
control improved. Children null for the GSTM1 allele were more susceptible to asthma
associated with environmental tobacco smoke; in older children, the GSTM1 null status
interacted with smoke exposure to reduce peak expiratory flow rate. (64)

Likewise,

children with asthma undergoing tonsillectomy with low glutathione s-transferase
expression in the airway may be more susceptible to environmental stress on the airway
from tonsillar inflammation, and more likely to improve from adenotonsillectomy.
An interferon induced protein, IFIT1, also increased in expression in matched blood
samples of children with uncontrolled asthma at baseline that improved control after
surgery, but not in control subjects or children with uncontrolled asthma that did not
improve. This may be relevant since IFIT1L was found to be down-regulated at baseline in
the blood of children with improved control as well. IFIT1 is an antiviral protein expressed
highly after viral infection. (65)
A number of other inflammatory proteins also changed in expression in the blood in
control subjects.

This is the first time that changes in gene expression related to

adenotonsillectomy are reported. These inflammatory proteins include interleukin-1 β,
cyclooxygenase-2 (PTGS2, the inducible form), adrenomedullin (ADM), and free fatty acid
receptor 2 (FFAR2, or Gpr43), all of which increased in expression. Granzyme-H, which
eliminates transformed and virus-infected cells, and NK cell lectin receptor (KLRF1) both
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decreased in expression over the study period. These changes support the notion that
adenotonsillectomy affects inflammatory pathways, regardless of asthma status. Of these,
IL-1β has previously been shown to exist in high concentrations in chronically inflamed
adenotonsillar tissue in children. (66) Others have been implicated in airway inflammation.
COX-2 is implicated in asthma, particular in nasal polyposis and aspirin-associated asthma.
(67) Adrenomedullin has been shown to suppress Th-2 related inflammation in mice. (68)
Mice deficient for Gpr43, a G protein coupled receptor in the gut for short chain fatty acids,
have hyperractive neutrophilic responses. (69) Granzyme-H targets adenovirus-infected
cells by neutralizing an inhibitor of Granzyme B. (70) KLRF1 has been shown to stimulate
CD8 T cells with an inflammatory NK-like phenotype. (71)
Limitations to the observational study include regression to the mean; however
longitudinal measurement of ACT scores and other measures of asthma control support our
findings. Though 29 ‘baseline’ ACT scores were collected during the post-operative followup period due to a change in study design, the median of these scores did not differ from the
median of scores truly collected at baseline. While this minimizes the possibility of a recall
bias due to the timing of the questionnaire, it does not eliminate such a possibility. Our
asthmatic group also had a high prevalence of poorly-controlled asthma and was thus more
severe than population data; however, this may be explained given our starting point of
children who were candidates for adenotonsillectomy, and thus, may have been more
connected to the medical system or more likely to have concurrent illnesses. Another
limitation is the effect of seasonal variability with a 6 month follow-up period; however, this
was controlled by enrolling participants year round. Though follow-up was targeted at six
months, actual mean follow-up time was 7 months, and ranged from 5 to 12 months. This
variability may have likewise affected post-operative results. Additionally, limited PFT data
in a young population made objective measures of asthma improvement difficult to obtain.
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Though this study was designed to specifically examine patients undergoing
adenotonsillectomy, the results suggest further studies comparing changes in asthma
control and chitinase activity to a non-surgical pediatric asthma population.
Finally, limitations to the gene expression analysis include heterogeneous cell types
in all three tissues, inability to perform post hoc correction for multiple comparisons due to
lack of results, and batch effect due to differences in sample processing including RIN
number and processing date. It is also curious that in the baseline tonsil samples, all
differentially expressed genes were on the Y chromosome, indicating an amplification or
detection anomaly.
This study demonstrates that a vast majority of children with asthma, and
particularly those with poorly-controlled asthma, undergoing adenotonsillectomy for
standard indications are likely to see an improvement in disease control. Clinical markers
associated with response include lower ACT scores at baseline, environmental triggers of
asthma, and higher serum chitinase activity at baseline. Additionally, a number of asthmarelated or inflammatory-related genes were found to be differentially expressed between
children with improved asthma control and children without improved control. SerpinB2, a
plasmin activation inhibitor previously shown to be related with asthma, may be of
particular interest as a marker of change in airway inflammation. This data suggest that the
surgery affects asthma control by modulating inflammation, rather than just altering airway
mechanics. The clinical, serum chitinase, and expression patterns could identify a subgroup
of children with poorly-controlled asthma likely to benefit from the surgery, and support
the rationale behind adenotonsillectomy as an intervention for asthma. Prospective studies
of children with asthma will be required to determine the clinical and biologic phenotype of
those most likely to have clinical improvement of asthma control from surgery.
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Figures and Tables
Figure 1
130 pediatric patients
(ages 2-18) undergoing
adenotonsillectomy enrolled

66 Asthmatics

64 Controls

62 (94%) with initial
bloodwork

60 (94%) with initial
bloodwork

58 subjects
achieved follow-up
(88%)

47 subjects
achieved follow-up
(73%)

42 subjects
completed followup bloodwork
(72%)

25 subjects
completed followup bloodwork
(53%)

Study design and follow-up rates for Asthma and Control cohorts undergoing
adenotonsillectomy

Levin et. al, 43

Figure 2
a . A C T S c o r e s in a ll c h ild r e n w it h a s t h m a ( n = 4 2 )
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Asthma Control Test (ACT) scores at baseline and follow-up
Median score displayed with interquartile ranges, error bars represent range of minimum and
maximum scores. p-values calculated by Wilcoxon Signed Rank Test.

Levin et. al, 44

Figure 3
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Chitotriosidase (CHIT1) and YKL-40 (CHI3L1) Genotypes in Asthma and Control
cohorts
p-values calculated by t-test.
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Figure 4
a . B a s e lin e C h itin a s e A c t iv it y a n d Y K L -4 0 L e v e l

b . P e r c e n t c h a n g e in C h it in a s e A c t iv ity
p = 0 .8 3

p < 0 .0 1

p = 0 .1 9

10

p = 0 .0 0 1

p = 0 .7 3

0%

120

80

6

60

4

40

2

20

0

C h itin a s e A c tiv ity

8

P e r c e n t c h a n g e in

100

Y K L -4 0 (n g /m l)

C h itin a s e A c tiv ity (n M /m l*h r)

12

0

-1 0 %

-2 0 %

-3 0 %

A s th m a

C o n tro l

A s th m a

C o n tro l

C o n t r o ls

A s t h m a t ic s

A s t h m a t ic s

(n = 6 5 )

(n = 6 4 )

(n = 6 5 )

(n = 6 4 )

(n = 2 2 )

Im p r o v e d

N o t Im p r o v e d

(n = 2 3 )

(n = 1 6 )

C h it in a s e A c t iv ity

Y K L -4 0 L e v e l

c . P e r c e n t c h a n g e in Y K L - 4 0 L e v e l

d . C h a n g e in C h it in a s e A c t iv it y in c h ild r e n w it h p o o r ly - c o n tr o lle d
a s th m a

20%

1 0 .0

p = 0 .7 6

p = 0 .7 6

p = 0 .8 1

0%

-1 0 %

N o t Im p ro v e d ( n = 3 )
7 .5

(n M /m l*h r)

10%

S e ru m C h itin a s e A c tiv ity

Y K L -4 0 L e v e l

P e r c e n t c h a n g e in

Im p ro v e d (n = 1 9 )

p < 0 .0 1
5 .0

2 .5

p = 1 .0 0

0 .0
C o n t r o ls

A s t h m a t ic s

A s t h m a t ic s

(n = 2 3 )

Im p r o v e d

N o t Im p r o v e d

(n = 2 3 )

(n = 1 8 )

B a s e lin e

F o llo w - U p

Chitinase Activity and YKL-40 Level in Asthma and Control cohorts
a. p-values calculated by Mann Whitney U Test. b-c. p-values calculated by Wilcoxon Signed Rank
Test. d. Poorly-controlled defined as baseline Asthma Control Test (ACT) Score < 20, rescue SABA
usage > 2 times/week, Emergency Room / Urgent Care Visits ≥ 2/year, or Oral Corticosteroid (OCS)
courses ≥ 2/year. p-values calculated by Wilcoxon Signed Rank Test. Baseline chitinase activity of
the improved group was also significantly higher than the not-improved group, p<0.05 by Mann
Whitney U Test.
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Figure 5
a.

b.

Concept: Adenotonsillectomy, Chitinases, and Asthma Control
a. CHIT1 polymorphism affects asthma prevalence in patients undergoing adenotonsillectomy
The genotypic data suggests that the CHIT1 polymorphism, which results in lower
chitotriosidase activity, correlates with asthma prevalence among patients undergoing
adenotonsillectomy. Chitinases may modulate the effect of environmental stressors
(including chitin) on airway inflammation, thus lowering asthma prevalence. Those with the
mutant CHIT1 allele have lower chitinase activity, and may be unable to modulate this
inflammation, possibly relating to upper airway disease including adenotonsillar
hypertrophy and inflammation, raising asthma prevalence.
b. Tonsillectomy induces changes in systemic inflammation associated with asthma
Meanwhile, longitudinal results suggest that patients with higher chitinase levels at baseline
with tonsillar hypertrophy/inflammation & asthma are more likely to see improvement after
tonsillectomy. This may be a reflection of both the airway-specific and systemic
inflammatory response to tonsillar hypertrophy and inflammation, and thus chitinase levels
decline after adenotonsillectomy correlating with a decrease in asthma severity.
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Table A
Baseline demographics and clinical characteristics of Asthma and Control cohorts
Asthmatics (n=66)

Controls (n=64)

p-value

Age - Mean (Range)

6.4 (2-17)

5.8 (2-18)

0.17*

Females – n (%)

25 (38)

33 (52)

0.16

‡

Males – n (%)

41 (62)

31 (48)

White/Caucasian

54 (82)

43 (67)

0.13

‡‡

Black/African American

11 (17)

20 (31)

Other

1 (1)

1 (2)

Hispanic and/or Latino Ethnicity – n (%)

32 (49)

19 (30)

0.03

‡

Comorbidities

Atopy – n (%)

49 (77)

32 (51)

<0.01

‡

History of GERD – n (%)

25 (38)

9 (14)

<0.01

‡

Sinusitis – n (%)

22 (33)

12 (19)

0.11

‡

18 (29)

17 (27)

1.00

‡

0.31

‡

0.72

‡‡

0.30

‡

Race – n (%)

Second Hand Smoke Exposure – n (%)
Weight (Described) – n (%)

Residence

Normal or Underweight

47 (71)

51 (80)

Overweight/Obese

19 (29)

13 (20)

Urban – n (%)

24 (37)

20 (31)

Suburban – n (%)

34 (52)

38 (60)

Rural – n (%)

7 (11)

6 (9)

Tonsillectomy Indication – n (%)
Hypertrophy, including OSA

46 (70)

52 (81)

Chronic/Recurrent Infection

18 (27)

12 (19)

FEV1 % Predicted – Median

93

112%

0.03*

IgE Levels (IU/mL) – Median

45.7

25.4

0.23*

* Mann-Whitney U Test; ‡Fisher’s Exact Test ; ‡‡Chi-Squared Test
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Table B
Change of clinical characteristics from baseline to follow-up in Asthma cohort (n=58)
Event frequency per 12 months

Baseline (mean)

Follow-up (mean)

Wilcoxon Signed
Rank Test

Emergency Room / Urgent Care Visits for Asthma

1.88

0.40

0.01

Oral corticosteroid courses

1.11

0.21

<0.01

Hospitalizations for Asthma

0.09

0.00

0.06

Missed School Days due to Asthma

3.86

2.00

0.01

Total Missed Parental Work Days

2.79

1.13

0.03
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Table C
Differentially expressed transcripts at baseline between children with asthma with
improved control versus those without improved control
Nasal Epithelium
p-value Fold Change

Gene

Description

HLA-DQB1|
HLA-DRB1|
HLA-DQB2|
HLA-DRB2|
HLA-DRB3|
HLA-DRB4|
HLA-DRB5|
ZNF749|
RNASE2|
hCG_1998957
GSTM1

major histocompatibility complex, class II, DQ beta 1 |
major histocompatibility complex, class II, DR beta 1 |
major histocompatibility complex, class II, DQ beta 2 |
major histocompatibility complex, class II, DR beta 2 |
major histocompatibility complex, class II, DR beta 3 |
major histocompatibility complex, class II, DR beta 4 |
major histocompatibility complex, class II, DR beta 5 |
zinc finger protein 749 |
ribonuclease, RNase A family, 2 (liver, eosinophil-derived
neurotoxin) | similar to hCG199264
glutathione S-transferase M1
major histocompatibility complex, class II, DR beta 5 |
major histocompatibility complex, class II, DQ beta 1 |
major histocompatibility complex, class II, DQ beta 2 |
major histocompatibility complex, class II, DR beta 1 |
major histocompatibility complex, class II, DR beta 2 |
major histocompatibility complex, class II, DR beta 3 |
major histocompatibility complex, class II, DR beta 4 |
zinc finger protein 749 |
ribonuclease, RNase A family, 2 (liver, eosinophil-derived
neurotoxin) | similar to hCG199264
serpin peptidase inhibitor, clade B (ovalbumin), member 2

0.014

2.57

0.030

-2.45

0.003

2.44

0.012

-2.10

HLA-DRB5|
HLA-DQB1|
HLA-DQB2|
HLA-DRB1|
HLA-DRB2|
HLA-DRB3|
HLA-DRB4|
ZNF749|
RNASE2|
hCG_1998957
FLJ21511

0.009

-1.96

SERPINB2

0.047

-1.96

CD177

0.002

1.93

ND6

NADH dehydrogenase, subunit 6 (complex I)

0.014

-1.91

SLC22A16

0.043

-1.82

NELL2

solute carrier family 22 (organic cation/carnitine transporter),
member 16
NEL-like 2 (chicken)

0.034

1.80

HLA-DQA1

major histocompatibility complex, class II, DQ alpha 1

0.003

-1.78

ST6GALNAC2

0.012

1.77

ADAMDEC1

ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-Nacetylgalactosaminide alpha-2,6-sialyltransferase 2
ADAM-like, decysin 1

0.018

1.76

killer cell immunoglobulin-like receptor

0.016

-1.74

KIR2DL3|
KIR2DS2|
KIR2DS4|
KIR2DL2|
KIR2DS1|
KIR2DL1|
KIR3DL2
CLDN3

0.010

-1.73

CYP2S1

cytochrome P450, family 2, subfamily S, polypeptide 1

0.005

-1.72

AHNAK2

AHNAK nucleoprotein 2

0.037

-1.68

VSNL1

visinin-like 1

0.044

1.67

SORD

sorbitol dehydrogenase

claudin 3
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0.021

1.66

GIMAP5

GTPase, IMAP family member 5

0.015

-1.62

ATP12A

ATPase, H+/K+ transporting, nongastric, alpha polypeptide

0.014

-1.60

PTPRT

protein tyrosine phosphatase, receptor type, T

0.040

1.60

SIGLEC10

sialic acid binding Ig-like lectin 10

0.009

-1.58

CLDN16

claudin 16

0.009

-1.56

LAMC2

laminin, gamma 2

0.029

-1.55

CKB

creatine kinase, brain

0.003

-1.54

KCND3

0.026

1.52

PRF1

potassium voltage-gated channel, Shal-related subfamily,
member 3
perforin 1 (pore forming protein)

0.017

-1.52

CDH13

cadherin 13, H-cadherin (heart)

0.003

-1.51

0.010

-1.50

GSTM4|
GSTM2
IGFBP2

glutathione S-transferase M4 |
glutathione S-transferase M2 (muscle)
insulin-like growth factor binding protein 2, 36kDa

0.031

-1.50

DENND2C

DENN/MADD domain containing 2C

0.043

1.50

LILRB4

leukocyte immunoglobulin-like receptor, subfamily B (with TM
and ITIM domains), member 4

Blood
p-value

Fold Change

Gene

Description

0.001

-1.62

XRRA1

X-ray radiation resistance associated 1

0.001

-1.61

OVOS

ovostatin

0.001

-1.60

OVOS2

ovostatin 2

0.023

-1.51

IFIT1L

interferon-induced protein with tetratricopeptide repeats 1-like

0.0004

-1.51

CPA3

carboxypeptidase A3 (mast cell)

Tonsil
p-value

Fold Change

Gene

Description

0.031

-3.39

UTY

ubiquitously transcribed tetratricopeptide repeat gene, Y-linked

0.035

-3.05

RPS4Y1

ribosomal protein S4, Y-linked 1

0.019

-2.80

JARID1D

jumonji, AT rich interactive domain 1D

0.030

-2.79

EIF1AY

eukaryotic translation initiation factor 1A, Y-linked

0.029

-2.79

DDX3Y

DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked

0.027

-2.66

USP9Y

0.025

-1.85

ZFY

ubiquitin specific peptidase 9, Y-linked (fat facets-like,
Drosophila)
zinc finger protein, Y-linked

Differentially expressed genes determined by non-corrected p-value <0.05, |Fold change|>1.5.
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Table D
Differentially expressed transcripts at follow-up versus baseline in matched blood
samples
Improved Asthma Control
p-value Fold Change Gene

Description

0.009

serpin peptidase inhibitor, clade B (ovalbumin), member 2

-1.54

SERPINB2

Non-Improved Asthma Control
p-value Fold Change Gene
0.029

1.52

SNHG10|
SCARNA13

Description
small nucleolar RNA host gene (non-protein coding) 10 |
small Cajal body-specific RNA 13

Improved Asthma Control Among Children with poorly controlled asthma
p-value Fold Change Gene
Description
0.012

2.59

RSAD2

radical S-adenosyl methionine domain containing 2

0.022

2.27

IFIT1

interferon-induced protein with tetratricopeptide repeats 1

0.039

2.07

HERC5

hect domain and RLD 5

0.024

1.73

EPSTI1

epithelial stromal interaction 1 (breast)

0.040

1.69

CD274

0.004

1.65

XK

X-linked Kx blood group (McLeod syndrome)

0.024

1.62

CMPK2

cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial

0.011

-1.60

SERPINB2

serpin peptidase inhibitor, clade B (ovalbumin), member 2

0.048

1.60

LAMP3

lysosomal-associated membrane protein 3

0.006

1.58

DDX60L

DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like

0.040

1.55

ELOVL7

0.037

1.52

OR2W3

ELOVL family member 7, elongation of long chain fatty acids
(yeast)
olfactory receptor, family 2, subfamily W, member 3

0.040

-1.51

SH2D2A

SH2 domain protein 2A

0.038

1.51

FECH

ferrochelatase (protoporphyria)

0.013

1.51

TSPAN7

tetraspanin 7

Control Subjects
p-value Fold Change

Gene

Description

0.042

1.77

KCNJ15

potassium inwardly-rectifying channel, subfamily J, member 15

0.011

1.75

GPR109A

G protein-coupled receptor 109A

0.014

1.74

GPR109B

G protein-coupled receptor 109B

0.023

1.70

ACSL1

acyl-CoA synthetase long-chain family member 1

0.009

1.69

PROK2

prokineticin 2

0.041

1.68

GK|GK3P

glycerol kinase | glycerol kinase 3 pseudogene

0.013

1.67

MGAM

maltase-glucoamylase (alpha-glucosidase)

0.040

1.66

ADM

adrenomedullin

0.042

-1.65

GZMH

granzyme H (cathepsin G-like 2, protein h-CCPX)
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0.027

-1.65

KLRF1

killer cell lectin-like receptor subfamily F, member 1

0.029

1.64

FFAR2

free fatty acid receptor 2

0.005

1.63

ROPN1L

ropporin 1-like

0.007

1.63

VNN3

vanin 3

0.032

1.58

GPR97

G protein-coupled receptor 97

0.046

1.58

UNQ9368

RTFV9368

0.030

1.53

IL1B

interleukin 1, beta

0.013

1.52

STEAP4

STEAP family member 4

0.036

1.51

KREMEN1

kringle containing transmembrane protein 1

0.031

1.50

PTGS2

prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
synthase and cyclooxygenase)

Differentially expressed genes determined by non-corrected p-value <0.05, |Fold change|>1.5.

